TERAPI PSORIASIS DI MASA PANDEMI COVID-19
DOI:
https://doi.org/10.33820/mdvi.v50i2.315Keywords:
psoriasis, autoimun, COVID-19, terapi biologiAbstract
Psoriasis is a chronic residive inflammatory skin disease caused by an autoimmune process. The worldwide prevalence of psoriasis ranges from 2-3% with the prevalence in Asia tends to be low, which is less than 0.5%. Psoriasis consists of erythematous scaly plaques and occurs most commonly on the elbows, knees, scalp, and lower back. Because of the reported frequent recurrences, psoriasis requires maintenance therapy in the form of systemic therapy such as retinoids, methotrexate, alefacept, and efalizumab. Coronavirus disease 2019 (COVID-19) is a respiratory infection caused by severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) and is highly contagious. The COVID-19 pandemic has a negative impact on psoriasis management and healthcare delivery. Infection of COVID-19 and its related medications can also affect the clinical severity and exacerbation in patient with psoriasis. Inadequate management of COVID-19 can trigger a cytokine storm and cause acute respiratory distress syndrome (ARDS), sepsis, and other complications. COVID-19 patients who experience a cytokine storm with elevated IL-6 and IL-17 may potentially experience psoriasis exacerbations. Biological therapy for psoriasis during pandemic should be carefully considered according to the individual patient’s condition.
Downloads
Download data is not yet available.
References
Meher C, D Roesyanto Ir, Rochadi K, Ashar T. Improving the quality of life in psoriasis patient through health promotion approach at Haji Adam Malik General Hospital, Medan, Indonesia. Asian J Pharm Clin Res. 2018;11(10):107-10.
2. Enamandram M, Kimball AB. Psoriasis Epidemiology: The interplay of genes and the environment. J Invest Dermatol. 2013; 133(2): 287–9.
3. Febriani D, Mulianto N. Profil pasien psoriasis di Poliklinik Kulit dan Kelamin RSUD Dr. Moewardi Surakarta periode januari 2017 - desember 2019. Universitas Sebelas Maret; 2020: 1-12.
4. Warren RB, Griffiths CEM. Systemic therapies for psoriasis: methotrexate, retinoids, and cyclosporine. Clin Dermatol. 2008;26(5):438–47.
5. Torres T, Pereira M, Lopes MJ, Rebelo C, Andrade P, Henrique M, Oliveira H, Ferreira P, Pinto GM, Brandão FM, Rozeira J. Dermatologists’ attitude towards psoriasis treatment during the COVID-19 pandemic. Drugs in context. 2021;10.
6. Kuang Y, Shen M, Wang Q, Xiao Y, Lv C, Luoz Y, dkk. Association of outdoor activity restriction and income loss with patirnt-reported outcimes of psoriasis during the COVID-19 pandemic: A web-based survey. J Am Acad Dermatol. 2020; 82(2): 670–2.
7. Schön MP, Erpenbeck L. The interleukin-23/interleukin-17 axis links adaptive and innate immunity in psoriasis. Front
Immunol. 2018; 9(6): 1–13.
8. Mahmudpour M, Roozbeh J, Keshavarz M, Farrokhi S,
Nabipour I. COVID-19 cytokine storm: The anger of
inflammation. Cytokine. 2020;133(4): 25-37.
9. Kutlu Ö, Metin A. Dermatological diseases presented before COVID-19: Are patients with psoriasis and superficial fungal infections more vulnerable to the COVID-19? Dermatol Ther.
2020; 33(4): 10–3.
10. World Health Organization. Therapeutics and COVID-19:
Living Guideline. Update 7 Desember 2021.
11. PDPI, PERKI, PAPDI, PERDATIN, IDAI. Revisi Protokol
Tata laksana COVID-19. Jakarta. Update 14 Juli 2021.
12. Tampa M, Nicolae I, Ene CD, Sarbu I, Matei C, Georgescu SR. Vitamin C and thiobarbituric acid reactive substances (TBARS) in psoriasis vulgaris related to psoriasis area
severity index (PASI). Rev Chim. 2017; 68(1): 43–7.
13. Gudjonsson JE, Elder JT. Psoriasis. In: Fitzpatrick’s Dermatology in General Medicine. Edisi ke-9. Goldsmith LA, Katz SL, Gilchrest BA, Paller AS, Leffell DJ, Wolff K,
editors.. New York: McGraw Hill; 2012. p. 309–50.
14. Barrea L, Savanelli MC, Di Somma C, Napolitano M, Megna M, Colao A, dkk. Vitamin D and its role in psoriasis: An overview of the dermatologist and nutritionist. Rev Endocr
Metab Disord. 2017; 18(2): 195–205.
15. Vatsalya V, Li F, Frimodig J, Gala KS, Srivastava S, Kong
60
MDVI
Vol. 50 No. 2 Tahun 2023; 54 - 61
M, Ramchandani VA, Feng W, Zhang X, McClain CJ. Repurposing Treatment of Wernicke-Korsakoff Syndrome for Th-17 Cell Immune Storm Syndrome and Neurological Symptoms in COVID-19: Thiamine Efficacy and Safety, In-Vitro Evidence and Pharmacokinetic Profile. Frontiers in pharmacology. 2020;11:2312.
16. Marik PE, Long A. ARDS complicating pustular psoriasis: Treatment with low-dose corticosteroids, vitamin C and thiamine. Case Reports. 2018:bcr-2017.
17. Hayakawa M, Izumi K, Higashida-Konishi M, Ushikubo M, Tsukamoto M, Akiya K, Araki K, Oshima H. Tocilizumab- induced psoriasis-like eruption resolved by shortening the dose interval in a patient with rheumatoid arthritis: a case- based review. Rheumatology international. 2019;39(1):161-6.
18. Gelfand JM, Armstrong AW, Bell S, Anesi GL, Blauvelt A, Calabrese C, dkk. National psoriasis foundation COVID-19 task force guidance for management of psoriatic disease during the pandemic: Version 1. J Am Acad Dermatol. 2020; 83(6): 1704–16.
19. Gelfand JM, Armstrong AW, Bell S, Anesi GL, Blauvelt A, Calabrese C, dkk. National psoriasis foundation COVID-19 task force guidance for management of psoriatic disease during the pandemic: Version 2 - Advances in psoriatic disease management, COVID-19 vaccines, and COVID-19 treatments. J Am Acad Dermatol. 2021; 84(5): 1254–68.
20. Annane D. Corticosteroids for COVID-19. Journal of Intensive Medicine. 2021.
21. Menter A, Korman NJ, Elmets CA, Feldman SR, Gelfand JM, Gordon KB, Gottlieb A, Koo JY, Lebwohl M, Lim HW, Van Voorhees AS. Guidelines of care for the management
of psoriasis and psoriatic arthritis: Section 5. Guidelines of care for the treatment of psoriasis with phototherapy and photochemotherapy. Journal of the American Academy of Dermatology. 2010;62(1):114-35.
22. Ricardo JW, Lipner SR. Considerations for safety in the use of systemic medications for psoriasis and atopic dermatitis during the COVID-19 pandemic. Dermatol Ther. 2020; 33(5): 143-56.
23. Safavi F, Nath A. Silencing of immune activation with methotrexate in patients with COVID-19. J Neurol Sci. 2020; 41(5): 6–8.
24. Nogueira M, Vender R, Torres T. Psoriasis, biologic therapy, and the pandemic of the 21st century. Drugs Context. 2020; 9(1): 17–20.
25. Puig L. The safety of ixekizumab in psoriasis drug therapy. Expert Opin Drug Saf. 2020; 19(2): 117–30.
26. Jenneck C, Novak N. The safety and efficacy of alefacept in the treatment of chronic plaque psoriasis. Ther Clin Risk Manag. 2007; 3(3): 411–20
27. Brownstone ND, Hong J, Mosca M, Hadeler E, Liao W, Bhutani T, Koo J. Biologic Treatments of Psoriasis: An Update for the Clinician. Biologics: Targets & Therapy. 2021;15:39.
28. Lernia V Di. Reply: Biologics for psoriasis during COVID-19 outbreak. J Am Dermatology. 2020; 82(6): 217–8.
29. Rønholt K, Iversen L. Old and new biological therapies for psoriasis. 2017; 4(5): 1-8.
30. Tsai YC, Tsai TF. Anti-interleukin and interleukin therapies for psoriasis: current evidence and clinical usefulness. Ther Adv Musculoskelet Dis. 2017; 9(11): 277–94.
2. Enamandram M, Kimball AB. Psoriasis Epidemiology: The interplay of genes and the environment. J Invest Dermatol. 2013; 133(2): 287–9.
3. Febriani D, Mulianto N. Profil pasien psoriasis di Poliklinik Kulit dan Kelamin RSUD Dr. Moewardi Surakarta periode januari 2017 - desember 2019. Universitas Sebelas Maret; 2020: 1-12.
4. Warren RB, Griffiths CEM. Systemic therapies for psoriasis: methotrexate, retinoids, and cyclosporine. Clin Dermatol. 2008;26(5):438–47.
5. Torres T, Pereira M, Lopes MJ, Rebelo C, Andrade P, Henrique M, Oliveira H, Ferreira P, Pinto GM, Brandão FM, Rozeira J. Dermatologists’ attitude towards psoriasis treatment during the COVID-19 pandemic. Drugs in context. 2021;10.
6. Kuang Y, Shen M, Wang Q, Xiao Y, Lv C, Luoz Y, dkk. Association of outdoor activity restriction and income loss with patirnt-reported outcimes of psoriasis during the COVID-19 pandemic: A web-based survey. J Am Acad Dermatol. 2020; 82(2): 670–2.
7. Schön MP, Erpenbeck L. The interleukin-23/interleukin-17 axis links adaptive and innate immunity in psoriasis. Front
Immunol. 2018; 9(6): 1–13.
8. Mahmudpour M, Roozbeh J, Keshavarz M, Farrokhi S,
Nabipour I. COVID-19 cytokine storm: The anger of
inflammation. Cytokine. 2020;133(4): 25-37.
9. Kutlu Ö, Metin A. Dermatological diseases presented before COVID-19: Are patients with psoriasis and superficial fungal infections more vulnerable to the COVID-19? Dermatol Ther.
2020; 33(4): 10–3.
10. World Health Organization. Therapeutics and COVID-19:
Living Guideline. Update 7 Desember 2021.
11. PDPI, PERKI, PAPDI, PERDATIN, IDAI. Revisi Protokol
Tata laksana COVID-19. Jakarta. Update 14 Juli 2021.
12. Tampa M, Nicolae I, Ene CD, Sarbu I, Matei C, Georgescu SR. Vitamin C and thiobarbituric acid reactive substances (TBARS) in psoriasis vulgaris related to psoriasis area
severity index (PASI). Rev Chim. 2017; 68(1): 43–7.
13. Gudjonsson JE, Elder JT. Psoriasis. In: Fitzpatrick’s Dermatology in General Medicine. Edisi ke-9. Goldsmith LA, Katz SL, Gilchrest BA, Paller AS, Leffell DJ, Wolff K,
editors.. New York: McGraw Hill; 2012. p. 309–50.
14. Barrea L, Savanelli MC, Di Somma C, Napolitano M, Megna M, Colao A, dkk. Vitamin D and its role in psoriasis: An overview of the dermatologist and nutritionist. Rev Endocr
Metab Disord. 2017; 18(2): 195–205.
15. Vatsalya V, Li F, Frimodig J, Gala KS, Srivastava S, Kong
60
MDVI
Vol. 50 No. 2 Tahun 2023; 54 - 61
M, Ramchandani VA, Feng W, Zhang X, McClain CJ. Repurposing Treatment of Wernicke-Korsakoff Syndrome for Th-17 Cell Immune Storm Syndrome and Neurological Symptoms in COVID-19: Thiamine Efficacy and Safety, In-Vitro Evidence and Pharmacokinetic Profile. Frontiers in pharmacology. 2020;11:2312.
16. Marik PE, Long A. ARDS complicating pustular psoriasis: Treatment with low-dose corticosteroids, vitamin C and thiamine. Case Reports. 2018:bcr-2017.
17. Hayakawa M, Izumi K, Higashida-Konishi M, Ushikubo M, Tsukamoto M, Akiya K, Araki K, Oshima H. Tocilizumab- induced psoriasis-like eruption resolved by shortening the dose interval in a patient with rheumatoid arthritis: a case- based review. Rheumatology international. 2019;39(1):161-6.
18. Gelfand JM, Armstrong AW, Bell S, Anesi GL, Blauvelt A, Calabrese C, dkk. National psoriasis foundation COVID-19 task force guidance for management of psoriatic disease during the pandemic: Version 1. J Am Acad Dermatol. 2020; 83(6): 1704–16.
19. Gelfand JM, Armstrong AW, Bell S, Anesi GL, Blauvelt A, Calabrese C, dkk. National psoriasis foundation COVID-19 task force guidance for management of psoriatic disease during the pandemic: Version 2 - Advances in psoriatic disease management, COVID-19 vaccines, and COVID-19 treatments. J Am Acad Dermatol. 2021; 84(5): 1254–68.
20. Annane D. Corticosteroids for COVID-19. Journal of Intensive Medicine. 2021.
21. Menter A, Korman NJ, Elmets CA, Feldman SR, Gelfand JM, Gordon KB, Gottlieb A, Koo JY, Lebwohl M, Lim HW, Van Voorhees AS. Guidelines of care for the management
of psoriasis and psoriatic arthritis: Section 5. Guidelines of care for the treatment of psoriasis with phototherapy and photochemotherapy. Journal of the American Academy of Dermatology. 2010;62(1):114-35.
22. Ricardo JW, Lipner SR. Considerations for safety in the use of systemic medications for psoriasis and atopic dermatitis during the COVID-19 pandemic. Dermatol Ther. 2020; 33(5): 143-56.
23. Safavi F, Nath A. Silencing of immune activation with methotrexate in patients with COVID-19. J Neurol Sci. 2020; 41(5): 6–8.
24. Nogueira M, Vender R, Torres T. Psoriasis, biologic therapy, and the pandemic of the 21st century. Drugs Context. 2020; 9(1): 17–20.
25. Puig L. The safety of ixekizumab in psoriasis drug therapy. Expert Opin Drug Saf. 2020; 19(2): 117–30.
26. Jenneck C, Novak N. The safety and efficacy of alefacept in the treatment of chronic plaque psoriasis. Ther Clin Risk Manag. 2007; 3(3): 411–20
27. Brownstone ND, Hong J, Mosca M, Hadeler E, Liao W, Bhutani T, Koo J. Biologic Treatments of Psoriasis: An Update for the Clinician. Biologics: Targets & Therapy. 2021;15:39.
28. Lernia V Di. Reply: Biologics for psoriasis during COVID-19 outbreak. J Am Dermatology. 2020; 82(6): 217–8.
29. Rønholt K, Iversen L. Old and new biological therapies for psoriasis. 2017; 4(5): 1-8.
30. Tsai YC, Tsai TF. Anti-interleukin and interleukin therapies for psoriasis: current evidence and clinical usefulness. Ther Adv Musculoskelet Dis. 2017; 9(11): 277–94.
Published
2023-08-01
How to Cite
Fiqnasyani, S. E., & Kusumawardani, A. (2023). TERAPI PSORIASIS DI MASA PANDEMI COVID-19. Media Dermato-Venereologica Indonesiana, 50(2), 54–61. https://doi.org/10.33820/mdvi.v50i2.315
Issue
Section
Tinjauan Pustaka
